Published in Acta Oncol on January 01, 2008
Cortactin: a multifunctional regulator of cellular invasiveness. Cell Adh Migr (2011) 1.36
Genomic imbalances in esophageal carcinoma cell lines involve Wnt pathway genes. World J Gastroenterol (2011) 0.88
Recently identified biomarkers that promote lymph node metastasis in head and neck squamous cell carcinoma. Cancers (Basel) (2011) 0.86
Expression of cortactin and survivin in renal cell carcinoma associated with tumor aggressiveness. World J Urol (2009) 0.85
An Old Story Retold: Loss of G1 Control Defines A Distinct Genomic Subtype of Esophageal Squamous Cell Carcinoma. Genomics Proteomics Bioinformatics (2015) 0.80
Integrins in invasive growth. J Clin Invest (2002) 1.96
Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol (2008) 1.92
A revised nomenclature for the human and rodent alpha-tubulin gene family. Genomics (2007) 1.68
Transforming growth factor beta induces rosettes of podosomes in primary aortic endothelial cells. Mol Cell Biol (2006) 1.50
Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood (2006) 1.40
PINCH1 regulates cell-matrix and cell-cell adhesions, cell polarity and cell survival during the peri-implantation stage. J Cell Sci (2005) 1.34
EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol (2007) 1.21
Molecular dissection of the ILK-PINCH-parvin triad reveals a fundamental role for the ILK kinase domain in the late stages of focal-adhesion maturation. J Cell Sci (2009) 1.19
Filopodia are dispensable for endothelial tip cell guidance. Development (2013) 1.16
PINCH2 is a new five LIM domain protein, homologous to PINCHand localized to focal adhesions. Exp Cell Res (2003) 1.16
Regulation of cell-matrix adhesion dynamics and Rac-1 by integrin linked kinase. FASEB J (2006) 1.14
ILK is required for the assembly of matrix-forming adhesions and capillary morphogenesis in endothelial cells. J Cell Sci (2004) 1.13
PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha. J Clin Invest (2010) 1.09
ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clin Cancer Res (2003) 1.06
JAK/STAT signalling pathway in colorectal cancer: a new biological target with therapeutic implications. Eur J Cancer (2006) 1.03
Modeling of salivary production recovery after radiotherapy using mixed models: determination of optimal dose constraint for IMRT planning and construction of convenient tools to predict salivary function. Int J Radiat Oncol Biol Phys (2008) 1.00
Free-flap head and neck reconstruction and quality of life: a 2-year prospective study. Laryngoscope (2008) 0.99
Inhibition of glycogen synthase kinase-3 activity triggers an apoptotic response in pancreatic cancer cells through JNK-dependent mechanisms. Carcinogenesis (2011) 0.98
Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer Chemother Pharmacol (2005) 0.95
Integrin-linked kinase and its partners: a modular platform regulating cell-matrix adhesion dynamics and cytoskeletal organization. Eur J Cell Biol (2005) 0.94
Randomised, multi-centre study of the usefulness of the heat and moisture exchanger (Provox HME®) in laryngectomised patients. Eur Arch Otorhinolaryngol (2011) 0.93
Results of vocal rehabilitation using tracheoesophageal voice prosthesis after total laryngectomy and their predictive factors. Eur Arch Otorhinolaryngol (2009) 0.92
Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. Thyroid (2014) 0.92
Head and neck reconstruction with free flaps: a report on 213 cases. Eur Arch Otorhinolaryngol (2007) 0.91
Epithelial tyrosine phosphatase SHP-2 protects against intestinal inflammation in mice. Mol Cell Biol (2013) 0.91
The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis. Mol Cancer (2010) 0.91
Significance of circulating tumor cell detection using the CellSearch system in patients with locally advanced head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol (2013) 0.90
Long-term quality of life and its predictive factors after oncologic surgery and microvascular reconstruction in patients with oral or oropharyngeal cancer. Eur Arch Otorhinolaryngol (2013) 0.89
Autocrine fibronectin directs matrix assembly and crosstalk between cell-matrix and cell-cell adhesion in vascular endothelial cells. J Cell Sci (2010) 0.88
Tumorigenic potential of miR-18A* in glioma initiating cells requires NOTCH-1 signaling. Stem Cells (2013) 0.87
Epidermal growth factor receptor protein detection in head and neck cancer patients: a many-faceted picture. Clin Cancer Res (2012) 0.86
Radical ablative surgery and radial forearm free flap (RFFF) reconstruction for patients with oral or oropharyngeal cancer: postoperative outcomes and oncologic and functional results. Acta Otolaryngol (2009) 0.85
[Parathyroid carcinoma]. Bull Cancer (2006) 0.85
Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition. Eur J Cancer (2008) 0.85
A specific approach for elderly patients with head and neck cancer. Anticancer Drugs (2011) 0.84
Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. Mol Cancer Ther (2005) 0.84
Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol (2011) 0.84
Regulation of fibronectin matrix assembly and capillary morphogenesis in endothelial cells by Rho family GTPases. Exp Cell Res (2009) 0.84
Quality of life after oral and oropharyngeal reconstruction with a radial forearm free flap: prospective study. J Otolaryngol Head Neck Surg (2009) 0.83
Pituicyte stellation is prevented by RhoA-or Cdc42-dependent actin polymerization. Cell Mol Neurobiol (2007) 0.83
Emerging molecular targeted therapies in the treatment of head and neck cancer. Expert Opin Emerg Drugs (2009) 0.83
Long-term functional outcomes and quality of life after oncologic surgery and microvascular reconstruction in patients with oral or oropharyngeal cancer. Acta Otolaryngol (2014) 0.83
Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells. Anticancer Drugs (2013) 0.82
RhoA inhibition is a key step in pituicyte stellation induced by A(1)-type adenosine receptor activation. Glia (2002) 0.82
The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data. BJU Int (2008) 0.82
Ablative surgery and free flap reconstruction for elderly patients with oral or oropharyngeal cancer: oncologic and functional outcomes. Acta Otolaryngol (2011) 0.81
Dynamic quantitative intravital imaging of glioblastoma progression reveals a lack of correlation between tumor growth and blood vessel density. PLoS One (2013) 0.81
Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02). Clin Cancer Res (2012) 0.81
Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience. Curr Opin Oncol (2006) 0.81
Synchronous parathyroid and papillary thyroid carcinomas. Thyroid (2009) 0.81
Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study. Anticancer Res (2011) 0.81
Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications. Curr Med Chem (2010) 0.80
Vasopressin and oxytocin reverse adenosine-induced pituicyte stellation via calcium-dependent activation of Cdc42. Eur J Neurosci (2002) 0.80
Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft. Eur J Cancer (2005) 0.80
Raf-1 activation prevents caspase 9 processing downstream of apoptosome formation. J Signal Transduct (2010) 0.79
Oral cavity squamous cell carcinoma in 260 patients aged 80years or more. Radiother Oncol (2009) 0.79
In papillary thyroid carcinoma, TIMP-1 expression correlates with BRAF (V600E) mutation status and together with hypoxia-related proteins predicts aggressive behavior. Virchows Arch (2013) 0.79
Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment. Nucleosides Nucleotides Nucleic Acids (2014) 0.78
Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinib. Oral Oncol (2010) 0.78
The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts. Oral Oncol (2011) 0.78
Salvage circular laryngopharyngectomy and radial forearm free flap for recurrent hypopharyngeal cancer. Laryngoscope (2013) 0.78
Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. Ther Drug Monit (2009) 0.78
Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line. Urol Oncol (2011) 0.78
Role of IL-8 induced angiogenesis in uveal melanoma. Invest New Drugs (2013) 0.78
ERK-associated changes in E2F4 phosphorylation, localization and transcriptional activity during mitogenic stimulation in human intestinal epithelial crypt cells. BMC Cell Biol (2013) 0.78
Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model. Oral Oncol (2011) 0.78
Impact of erythropoietin on the effects of irradiation under hypoxia. J Cancer Res Clin Oncol (2009) 0.78
Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study. Invest New Drugs (2012) 0.77
Impact of patient comorbidities on head and neck microvascular reconstruction. A report on 423 cases. Eur Arch Otorhinolaryngol (2012) 0.77
Contemporary therapeutic management of locally advanced hypopharyngeal cancer: oncologic and functional outcomes - a report on 100 cases. Acta Otolaryngol (2015) 0.77
Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines. Urol Oncol (2012) 0.75
Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study. Anticancer Drugs (2016) 0.75
DPD testing must remain a recommended option, but not a recommended routine test. Ann Oncol (2017) 0.75
[Upper aerodigestive tract carcinoma: therapeutic management]. Presse Med (2007) 0.75
Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab. Eur J Cancer (2004) 0.75
[Sino nasal polyps: true and false tumors]. Ann Pathol (2011) 0.75